Literature DB >> 26726757

CD33 is frequently expressed in cases of myelodysplastic syndrome and chronic myelomonocytic leukemia with elevated blast count.

David Sanford1, Guillermo Garcia-Manero1, Jeffrey Jorgensen1, Sergej Konoplev1, Sherry Pierce1, Jorge Cortes1, Hagop Kantarjian1, Farhad Ravandi1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 26726757      PMCID： PMC5594739          DOI： 10.3109/10428194.2015.1122780

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN： 1026-8022


× No keyword cloud information.
  20 in total

1.  The World Health Organization classification of neoplastic diseases of the haematopoietic and lymphoid tissues: Report of the Clinical Advisory Committee Meeting, Airlie House, Virginia, November 1997.

Authors:  N L Harris; E S Jaffe; J Diebold; G Flandrin; H K Muller-Hermelink; J Vardiman; T A Lister; C D Bloomfield
Journal:  Histopathology       Date:  2000-01       Impact factor: 5.087

2.  CD33-specific chimeric antigen receptor T cells exhibit potent preclinical activity against human acute myeloid leukemia.

Authors:  S S Kenderian; M Ruella; O Shestova; M Klichinsky; V Aikawa; J J D Morrissette; J Scholler; D Song; D L Porter; M Carroll; C H June; S Gill
Journal:  Leukemia       Date:  2015-02-27       Impact factor: 11.528

3.  CD33 expression and P-glycoprotein-mediated drug efflux inversely correlate and predict clinical outcome in patients with acute myeloid leukemia treated with gemtuzumab ozogamicin monotherapy.

Authors:  Roland B Walter; Ted A Gooley; Vincent H J van der Velden; Michael R Loken; Jacques J M van Dongen; David A Flowers; Irwin D Bernstein; Frederick R Appelbaum
Journal:  Blood       Date:  2007-01-16       Impact factor: 22.113

4.  Restricted expression of an early myeloid and monocytic cell surface antigen defined by monoclonal antibody M195.

Authors:  M Tanimoto; D A Scheinberg; C Cordon-Cardo; D Huie; B D Clarkson; L J Old
Journal:  Leukemia       Date:  1989-05       Impact factor: 11.528

5.  Differences in CD33 intensity between various myeloid neoplasms.

Authors:  Iman Jilani; Elihu Estey; Yang Huh; Youngson Joe; Taghi Manshouri; Marwan Yared; Francis Giles; Hagop Kantarjian; Jorge Cortes; Deborah Thomas; Michael Keating; Emil Freireich; Maher Albitar
Journal:  Am J Clin Pathol       Date:  2002-10       Impact factor: 2.493

6.  A phase 3 study of gemtuzumab ozogamicin during induction and postconsolidation therapy in younger patients with acute myeloid leukemia.

Authors:  Stephen H Petersdorf; Kenneth J Kopecky; Marilyn Slovak; Cheryl Willman; Thomas Nevill; Joseph Brandwein; Richard A Larson; Harry P Erba; Patrick J Stiff; Robert K Stuart; Roland B Walter; Martin S Tallman; Leif Stenke; Frederick R Appelbaum
Journal:  Blood       Date:  2013-04-16       Impact factor: 22.113

7.  Influence of CD33 expression levels and ITIM-dependent internalization on gemtuzumab ozogamicin-induced cytotoxicity.

Authors:  Roland B Walter; Brian W Raden; Darren M Kamikura; Jonathan A Cooper; Irwin D Bernstein
Journal:  Blood       Date:  2004-09-28       Impact factor: 22.113

Review 8.  Addition of gemtuzumab ozogamicin to induction chemotherapy in adult patients with acute myeloid leukaemia: a meta-analysis of individual patient data from randomised controlled trials.

Authors:  Robert K Hills; Sylvie Castaigne; Frederick R Appelbaum; Jacques Delaunay; Stephen Petersdorf; Megan Othus; Elihu H Estey; Hervé Dombret; Sylvie Chevret; Norbert Ifrah; Jean-Yves Cahn; Christian Récher; Lucy Chilton; Anthony V Moorman; Alan K Burnett
Journal:  Lancet Oncol       Date:  2014-07-06       Impact factor: 41.316

9.  Hydroxyurea, azacitidine and gemtuzumab ozogamicin therapy in patients with previously untreated non-M3 acute myeloid leukemia and high-risk myelodysplastic syndromes in the elderly: results from a pilot trial.

Authors:  Sucha Nand; John Godwin; Scott Smith; Kevin Barton; Laura Michaelis; Serhan Alkan; Ranjitha Veerappan; Karen Rychlik; Eliza Germano; Patrick Stiff
Journal:  Leuk Lymphoma       Date:  2008-11

10.  Addition of gemtuzumab ozogamicin to induction chemotherapy improves survival in older patients with acute myeloid leukemia.

Authors:  Alan K Burnett; Nigel H Russell; Robert K Hills; Jonathan Kell; Sylvie Freeman; Lars Kjeldsen; Ann E Hunter; John Yin; Charles F Craddock; Inge Hoegh Dufva; Keith Wheatley; Donald Milligan
Journal:  J Clin Oncol       Date:  2012-07-30       Impact factor: 44.544
View more
  2 in total

1.  Modelling acute myeloid leukemia (AML): What's new? A transition from the classical to the modern.

Authors:  Annachiara Dozzo; Aoife Galvin; Jae-Won Shin; Santo Scalia; Caitriona M O'Driscoll; Katie B Ryan
Journal:  Drug Deliv Transl Res       Date:  2022-08-05       Impact factor: 5.671

2.  Polo-like kinase inhibitor volasertib marginally enhances the efficacy of the novel Fc-engineered anti-CD33 antibody BI 836858 in acute myeloid leukemia.

Authors:  Bhavani Gopalakrishnan; Carolyn Cheney; Rajeswaran Mani; Xiaokui Mo; Donna Bucci; Alison Walker; Rebecca Klisovic; Bhavana Bhatnagar; Katherine Walsh; Bjoern Rueter; Irene C Waizenegger; Karl-Heinz Heider; William Blum; Sumithira Vasu; Natarajan Muthusamy
Journal:  Oncotarget       Date:  2018-01-03
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.